Royalty Pharma (RPRX) Stock Forecast & Price Target

$33.42 +0.32 (+0.95%)

As of 11:15 AM Eastern

Royalty Pharma - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 6 Analyst Ratings

Sell
0

Hold
1

Buy
5

Based on 6 Wall Street analysts who have issued ratings for Royalty Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 1 has given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for RPRX.

Consensus Price Target

$41.60
24.46% Upside

According to the 6 analysts' twelve-month price targets for Royalty Pharma, the average price target is $41.60. The highest price target for RPRX is $51.00, while the lowest price target for RPRX is $28.00. The average price target represents a forecasted upside of 24.46% from the current price of $33.43.

Get the Latest News and Ratings for RPRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Royalty Pharma and its competitors.

RPRX Analyst Ratings Over Time

Type	Current Forecast 2/22/24 to 2/21/25	1 Month Ago 1/23/24 to 1/22/25	3 Months Ago 11/24/23 to 11/23/24	1 Year Ago 2/22/23 to 2/22/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$41.60	$41.67	$41.67	$52.25
Forecasted Upside	24.46% Upside	38.52% Upside	57.65% Upside	68.44% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Buy

RPRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RPRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Royalty Pharma Stock vs. The Competition

Type	Royalty Pharma	Finance Companies	S&P 500
Consensus Rating Score	3.00	2.51	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	24.81% Upside	23.93% Upside	12.83% Upside
News Sentiment Rating	Positive News See Recent RPRX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/24/2024	TD Cowen 5 of 5 stars	M. Nedelcovych Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/25/2024	Citigroup 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$60.00 ➝ $40.00	+47.17%
8/14/2024	The Goldman Sachs Group 2 of 5 stars		Boost Target	Buy ➝ Buy	$50.00 ➝ $51.00	+89.87%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$48.00 ➝ $51.00	+90.65%
6/3/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$28.00	+2.83%
4/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$40.00 ➝ $38.00	+30.81%
2/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$45.00 ➝ $42.00	+39.21%
4/6/2023	Tigress Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$57.00 ➝ $60.00	+64.93%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:16 AM ET.

Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, February 16, 2025. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com.

Royalty Pharma
Bull Case

Here are some ways that investors could benefit from investing in Royalty Pharma plc:

The company has recently increased its annual dividend to $0.88, reflecting a yield of 2.77%. This is a positive change from the previous quarterly dividend, indicating a commitment to returning value to shareholders.
Royalty Pharma plc has a strong market capitalization of $19.10 billion, which suggests stability and the potential for growth in the biopharmaceutical sector.
With a P/E ratio of 16.75, the stock may be considered reasonably valued compared to its earnings, making it an attractive option for investors looking for growth opportunities.
Institutional investors and hedge funds own 54.35% of the company's stock, indicating strong confidence from large financial entities in the company's future performance.
The stock price is currently around $28.30, which is above its 200-day simple moving average of $27.74, suggesting a positive trend in the stock's performance.

Royalty Pharma
Bear Case

Investors should be bearish about investing in Royalty Pharma plc for these reasons:

The stock has recently experienced a slight decline of 0.1%, which may indicate potential volatility or a lack of momentum in the short term.
Royalty Pharma plc has a debt-to-equity ratio of 0.64, which, while not excessively high, suggests that the company does carry some debt that could impact its financial flexibility.
The current ratio and quick ratio are both at 1.54, which indicates that while the company can cover its short-term liabilities, it may not have a significant buffer for unexpected expenses.
Recent increases in institutional holdings may lead to a lack of liquidity in the stock, as large investors may hold onto their shares rather than trading them frequently.
As a biopharmaceutical company, Royalty Pharma plc is subject to regulatory risks and market competition, which could impact its profitability and growth prospects.

RPRX Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Royalty Pharma is $41.60, with a high forecast of $51.00 and a low forecast of $28.00.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There is currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPRX shares.
: According to analysts, Royalty Pharma's stock has a predicted upside of 24.46% based on their 12-month stock forecasts.
: Over the previous 90 days, Royalty Pharma's stock had 1 upgrade by analysts.
: Royalty Pharma has been rated by research analysts at TD Cowen in the past 90 days.
: Analysts like Royalty Pharma more than other "finance" companies. The consensus rating for Royalty Pharma is Buy while the average consensus rating for "finance" companies is Moderate Buy. Learn more on how RPRX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:RPRX) was last updated on 2/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Stock Forecast & Price Target